GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award
GIMOTI recognized as a major disruptor in the gastroenterology field, including several large global pharmaceutical companies
Vote for GIMOTI as 2022 Healio Industry Breakthrough Product via Survey
Related news for (EVOK)
- Morning Surge: Biotech Leads the Way as Innovation Meets Momentum
- Don’t Miss Out: MoBot’s Latest Stock Updates 08/21/25 08:00 AM
- Today’s Top Performers: MoBot’s Market Review 08/21/25 07:00 AM
- Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book
- 24/7 Market News Snapshot 21 August, 2025 – Evoke Pharma, Inc. (NASDAQ:EVOK)